Telix Pharmaceuticals Limited

7 articles with Telix Pharmaceuticals Limited

• Heidelberg Pharma Receives Milestone Payment from Partner Telix

  6/5/2019

  Heidelberg Pharma AG announced that it has received a milestone payment of 250 TUSD from its cooperation partner Telix Pharmaceuticals Limited, Melbourne, Australia,.

• Telix Pharmaceuticals and Cardinal Health Enter into Distribution Agreement for Prostate Cancer Imaging

  10/3/2018

  Telix Pharmaceuticals (US) Inc. today announced that it has entered into a distribution agreement with Cardinal Health (NYSE:CAH).

• Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe

  8/23/2018

  Heidelberg Pharma AG (ISIN DE000A11QVV0 / WKN A11QVV / WL6) today announced that its partner Telix Pharmaceuticals Limited ("Telix") (ASX:TLX), has submitted a Clinical Trial Application (CTA) to initiate a Phase III trial in Europe for 89Zr-DFO-girentuximab (TLX250) for the imaging of renal (kidney) cancer with Positron Emission Tomography (PET).

• Telix and Nihon Medi-Physics to Collaborate on Renal Cancer Imaging for the Japanese Market

  8/15/2018

  Telix Pharmaceuticals Limited and Nihon Medi-Physics Co., Ltd. have today announced that they have entered into a memorandum of understanding (MOU) for a commercial partnership in renal cancer imaging for the Japanese market.

• First Patient Imaged in Prostate Imaging Study

  8/12/2018

  Telix Pharmaceuticals Limited is pleased to announce that Memorial Sloan Kettering Cancer Center (“MSK”) has imaged the first two patients in a 500 patient Phase II Expanded-Access Investigational New Drug (IND) study for imaging prostate cancer with the investigational agent 68Ga-PSMA-11

• Telix and Isologic conclude manufacturing agreement for North America

  6/25/2018

  Telix Pharmaceuticals Limited has announced a technology transfer and manufacturing agreement with ISOLOGIC Innovative Radiopharmaceuticals

• 

  Telix Pharmaceuticals Establishes Japanese Subsidiary, Appoints Key Executives

  1/15/2018

  The purpose of the subsidiary is to support the Company’s Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in the Japan, an important market for Telix’s products.